MBL Wealth LLC Acquires New Holdings in Astrazeneca Plc $AZN

MBL Wealth LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,754 shares of the company’s stock, valued at approximately $253,000.

Other large investors have also added to or reduced their stakes in the company. Bangor Savings Bank raised its holdings in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Triumph Capital Management bought a new position in Astrazeneca in the 3rd quarter valued at approximately $25,000. YANKCOM Partnership bought a new position in Astrazeneca in the 4th quarter valued at approximately $31,000. Rakuten Investment Management Inc. bought a new position in Astrazeneca in the 3rd quarter valued at approximately $31,000. Finally, JPL Wealth Management LLC bought a new position in Astrazeneca in the 3rd quarter valued at approximately $35,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 1.8%

Shares of AZN stock opened at $204.44 on Thursday. The company has a market cap of $317.06 billion, a PE ratio of 31.21, a P/E/G ratio of 1.53 and a beta of 0.35. Astrazeneca Plc has a 52 week low of $122.48 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AZN. Wall Street Zen lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. HSBC reiterated a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, Weiss Ratings initiated coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.